Press Releases : AVROBIO

AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update

Following positive regulatory feedback, plan to initiate registrational global Phase 2/3 clinical trial for Gaucher disease type 3 (GD3) in second half 2023, subject to regulatory alignment Patient dosing completed in collaborator-sponsored Phase 1/2 clinical trial for cystinosis; plan to initiate

Mar 23, 2023

AVROBIO to Participate in Cowen’s 43rd Annual Health Care Conference

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 3, 2023-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in a panel titled

Mar 03, 2023

AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium™ 2023

Four platform presentations and two posters with data on AVROBIO’s lysosomal disorder programs to be presented CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 9, 2023-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease,

Feb 09, 2023

AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 5, 2023-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 7,500 restricted stock units (RSUs) to one new

Alert type
Quote
SEC Filing
Event
News

Press Releases

Site - Secondary Menu